CIRROSIS HEPATICA POR NASH PDF

Desde entonces aumentan los conocimientos sobre ella. Estos receptores nucleares abundan en el tejido adiposo y existen en menor cantidad en los hepatocitos. El autor manifiesta que hay que tener en cuenta lo poco que se conoce de esta enfermedad y que los resultados de las investigaciones son conflictivos. La obesidad y los signos de resistencia a la insulina por ej.

Author:Majin Guzragore
Country:Finland
Language:English (Spanish)
Genre:Environment
Published (Last):18 September 2011
Pages:425
PDF File Size:2.68 Mb
ePub File Size:3.95 Mb
ISBN:807-5-11361-392-1
Downloads:43237
Price:Free* [*Free Regsitration Required]
Uploader:Zurg



Desde entonces aumentan los conocimientos sobre ella. Estos receptores nucleares abundan en el tejido adiposo y existen en menor cantidad en los hepatocitos. El autor manifiesta que hay que tener en cuenta lo poco que se conoce de esta enfermedad y que los resultados de las investigaciones son conflictivos.

La obesidad y los signos de resistencia a la insulina por ej. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Mayo Clin Proc. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. The natural history of non-alcoholic Figure 2. Mean scores for inflammation, ballooning necrosis, steatosis, and fibrosis in liver biopsy specimens before and after treatment with a hypocaloric diet kcal per day plus pioglitazone, or a hypocaloric diet plus placebo, in 55 patients with impaired glucose tolerance or T2DM and liver biopsy-confirmed NASH.

Between-group differences were compared by means of the Wilcoxon rank-sum test. Withingroup differences before versus after treatment were compared by means of the Wilcoxon signed-rank test. Reproduced, with permission, from Belfort R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.

Diabetes Care. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Nonalcoholic fatty liver disease. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery. J Gastrointest Surg. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.

J Hepatol. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. Liver abnormalities in severely obese subjects: effects of drastic weight loss after gastroplasty. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Nonalcoholic fatty liver disease in severely obese subjects. Amarapurkar D, Patel N. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop Gastroenterol. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Nonalcoholic fatty liver disease in patients with type 2 diabetes.

Clin Gastroenterol Hepatol. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. Maheshwari A, Paul JT. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Relations between carotid artery wall thickness and liver histology in subjects with non-alcoholic fatty liver disease.

Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Pessayre D, Fromenty B. NASH: a mitochondrial disease. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. The effect of pioglitazone on peroxisome proliferator-activated receptorgamma target genes related to lipid storage in vivo.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease.

The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. Pioglitazone treatment activates AMPactivated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun. Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase.

Nat Med. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Adiponectin and its receptors in non-alcoholic steatohepatitis. Peroxisome proliferator- activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy. Pioglitazone time-dependently reduces tumour necrosis factor-a level in muscle and improves metabolic abnormalities in Wistar fatty rats.

Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferatoractivated receptor-gamma, pioglitazone. J Pharmacol Exp Ther. Angulo P. The fluctuation of serum levels of aminotransferase in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol.

Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Ann Intern Med. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis.

Adams LA, Paul A. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation.

Liver Transpl. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings.

The utility of radiological imaging in nonalcoholic fatty liver disease.

EDUARD FUCHS ILLUSTRIERTE SITTENGESCHICHTE PDF

Esteatosis hepática no alcohólica

La nueva pandemia del milenio. Con permiso de McCullough AJ Figura 1. Archivo personal.

INTELLIGENZA EMOTIVA PER UN FIGLIO GOTTMAN PDF

Enfermedad del hígado graso no alcohólico y esteatohepatitis no alcohólica

Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Figura 1. Figura 2. Figura 3. Figura 4.

GOLF TURIZMI PDF

¿Se puede revertir la enfermedad del hígado graso no alcohólico?

.

Related Articles